Restricting a-synuclein transport into mitochondria by inhibition of a-synuclein-VDAC complexation as a potential therapeutic target for Parkinson's disease treatment.
Restricting a-synuclein transport into mitochondria by inhibition of a-synuclein-VDAC complexation as a potential therapeutic target for Parkinson's disease treatment. Cell Mol Life Sci. 2022 Jun 19; 79(7):368.